MONDAY, Nov. 22, 2021 (HealthDay Information)
Pfizer Inc. claimed Monday that its coronavirus vaccine offers lengthy-phrase defense in youth ages 12-15, in accordance to facts from a corporation scientific trial that included additional than 2,200 members.
In a firm scientific demo that included additional than 2,200 adolescents, receiving two doses of the vaccine was 100% efficient against the coronavirus from seven times to 4 months following the 2nd shot, Pfizer said in a news launch.
There were being 30 confirmed symptomatic COVID-19 conditions in the trial, and all ended up in the placebo group.
In August, the U.S. Food and Drug Administration granted complete approval of the vaccine for use in people today aged 16 and more mature. The vaccine has been granted unexpected emergency use authorization for youth ages 12-15, but Pfizer will post this new facts to the Food and drug administration as it seeks comprehensive acceptance for that age group.
“As the world health and fitness community will work to maximize the number of vaccinated people today all over the globe, these supplemental knowledge present more self-assurance in our vaccine’s basic safety and success profile in adolescents,” Pfizer CEO Albert Bourla mentioned. “This is particularly vital as we see prices of COVID-19 climbing in this age team in some locations, though vaccine uptake has slowed.”
On Friday, the Food and drug administration approved Pfizer and Moderna COVID-19 vaccine booster pictures for all grown ups aged 18 or more mature.
Much more information
Check out the U.S. Meals and Drug Administration for far more on COVID vaccines.
Resource: Pfizer INc., information release, Nov. 22, 2021
Copyright © 2021 HealthDay. All rights reserved.